Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients
We have previously shown that immunodominant MBP peptides encapsulated in mannosylated liposomes (Xemys) effectively suppressed experimental allergic encephalomyelitis (EAE). Within the frames of the successfully completed phase I clinical trial, we investigated changes in the serum cytokine profile...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2016/2847232 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850229236141391872 |
|---|---|
| author | Yakov Lomakin Alexey Belogurov Irina Glagoleva Alexey Stepanov Konstantin Zakharov John Okunola Ivan Smirnov Dmitry Genkin Alexander Gabibov |
| author_facet | Yakov Lomakin Alexey Belogurov Irina Glagoleva Alexey Stepanov Konstantin Zakharov John Okunola Ivan Smirnov Dmitry Genkin Alexander Gabibov |
| author_sort | Yakov Lomakin |
| collection | DOAJ |
| description | We have previously shown that immunodominant MBP peptides encapsulated in mannosylated liposomes (Xemys) effectively suppressed experimental allergic encephalomyelitis (EAE). Within the frames of the successfully completed phase I clinical trial, we investigated changes in the serum cytokine profile after Xemys administration in MS patients. We observed a statistically significant decrease of MCP-1/CCL2, MIP-1β/CCL4, IL-7, and IL-2 at the time of study completion. In contrast, the serum levels of TNF-α were remarkably elevated. Our data suggest that the administration of Xemys leads to a normalization of cytokine status in MS patients to values commonly reported for healthy subjects. These data are an important contribution for the upcoming Xemys clinical trials. |
| format | Article |
| id | doaj-art-28018ba28c0140b2941bca299eeabea3 |
| institution | OA Journals |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-28018ba28c0140b2941bca299eeabea32025-08-20T02:04:18ZengWileyMediators of Inflammation0962-93511466-18612016-01-01201610.1155/2016/28472322847232Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis PatientsYakov Lomakin0Alexey Belogurov1Irina Glagoleva2Alexey Stepanov3Konstantin Zakharov4John Okunola5Ivan Smirnov6Dmitry Genkin7Alexander Gabibov8Institute of Bioorganic Chemistry RAS, Moscow 117997, RussiaInstitute of Bioorganic Chemistry RAS, Moscow 117997, RussiaInstitute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420012, RussiaInstitute of Bioorganic Chemistry RAS, Moscow 117997, RussiaOJSC Pharmsynthez, Saint Petersburg 197110, RussiaInstitute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420012, RussiaInstitute of Bioorganic Chemistry RAS, Moscow 117997, RussiaOJSC Pharmsynthez, Saint Petersburg 197110, RussiaInstitute of Bioorganic Chemistry RAS, Moscow 117997, RussiaWe have previously shown that immunodominant MBP peptides encapsulated in mannosylated liposomes (Xemys) effectively suppressed experimental allergic encephalomyelitis (EAE). Within the frames of the successfully completed phase I clinical trial, we investigated changes in the serum cytokine profile after Xemys administration in MS patients. We observed a statistically significant decrease of MCP-1/CCL2, MIP-1β/CCL4, IL-7, and IL-2 at the time of study completion. In contrast, the serum levels of TNF-α were remarkably elevated. Our data suggest that the administration of Xemys leads to a normalization of cytokine status in MS patients to values commonly reported for healthy subjects. These data are an important contribution for the upcoming Xemys clinical trials.http://dx.doi.org/10.1155/2016/2847232 |
| spellingShingle | Yakov Lomakin Alexey Belogurov Irina Glagoleva Alexey Stepanov Konstantin Zakharov John Okunola Ivan Smirnov Dmitry Genkin Alexander Gabibov Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients Mediators of Inflammation |
| title | Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients |
| title_full | Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients |
| title_fullStr | Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients |
| title_full_unstemmed | Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients |
| title_short | Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients |
| title_sort | administration of myelin basic protein peptides encapsulated in mannosylated liposomes normalizes level of serum tnf α and il 2 and chemoattractants ccl2 and ccl4 in multiple sclerosis patients |
| url | http://dx.doi.org/10.1155/2016/2847232 |
| work_keys_str_mv | AT yakovlomakin administrationofmyelinbasicproteinpeptidesencapsulatedinmannosylatedliposomesnormalizeslevelofserumtnfaandil2andchemoattractantsccl2andccl4inmultiplesclerosispatients AT alexeybelogurov administrationofmyelinbasicproteinpeptidesencapsulatedinmannosylatedliposomesnormalizeslevelofserumtnfaandil2andchemoattractantsccl2andccl4inmultiplesclerosispatients AT irinaglagoleva administrationofmyelinbasicproteinpeptidesencapsulatedinmannosylatedliposomesnormalizeslevelofserumtnfaandil2andchemoattractantsccl2andccl4inmultiplesclerosispatients AT alexeystepanov administrationofmyelinbasicproteinpeptidesencapsulatedinmannosylatedliposomesnormalizeslevelofserumtnfaandil2andchemoattractantsccl2andccl4inmultiplesclerosispatients AT konstantinzakharov administrationofmyelinbasicproteinpeptidesencapsulatedinmannosylatedliposomesnormalizeslevelofserumtnfaandil2andchemoattractantsccl2andccl4inmultiplesclerosispatients AT johnokunola administrationofmyelinbasicproteinpeptidesencapsulatedinmannosylatedliposomesnormalizeslevelofserumtnfaandil2andchemoattractantsccl2andccl4inmultiplesclerosispatients AT ivansmirnov administrationofmyelinbasicproteinpeptidesencapsulatedinmannosylatedliposomesnormalizeslevelofserumtnfaandil2andchemoattractantsccl2andccl4inmultiplesclerosispatients AT dmitrygenkin administrationofmyelinbasicproteinpeptidesencapsulatedinmannosylatedliposomesnormalizeslevelofserumtnfaandil2andchemoattractantsccl2andccl4inmultiplesclerosispatients AT alexandergabibov administrationofmyelinbasicproteinpeptidesencapsulatedinmannosylatedliposomesnormalizeslevelofserumtnfaandil2andchemoattractantsccl2andccl4inmultiplesclerosispatients |